bapineuzumab

Known as: Anti-human beta-amyloid Monoclonal Antibody 3D-6, Humanized 3D-6 Monoclonal Antibody 
A humanized monoclonal antibody (IgG1) raised against amyloid beta peptides with Alzheimer disease treatment application. Bapineuzumab recognizes and… (More)
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
BACKGROUND Alzheimer's disease (AD) is a globally prevalent neurodegenerative condition, clinically characterized by progressive… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2016
2016
Our objective was to evaluate the efficacy (clinical and biomarker) and safety of intravenous bapineuzumab in patients with mild… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
Highly Cited
2014
Highly Cited
2014
BACKGROUND Bapineuzumab, a humanized anti-amyloid-beta monoclonal antibody, is in clinical development for the treatment of… (More)
  • table 1
  • figure 1
  • table 2
  • table 3
Is this relevant?
2014
2014
To the Editor: Salloway et al. (Jan. 23 issue)1 report on two trials of bapineuzumab in mild-tomoderate Alzheimer’s disease, and… (More)
Is this relevant?
2013
2013
Bapineuzumab is a humanized antibody developed by Pfizer and Johnson & Johnson targeting the amyloid (Aβ) plaques that underlie… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2012
Highly Cited
2012
BACKGROUND Given the slow and variable clinical course of Alzheimer disease, very large and extended clinical trials are needed… (More)
  • table 1
  • figure 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
Review
2011
Review
2011
Recent advances in our understanding of the neurobiology of Alzheimer's disease (AD) have led to the development of putative… (More)
Is this relevant?
Highly Cited
2010
Highly Cited
2010
The safety, tolerability, and pharmacokinetics (PKs) of bapineuzumab (AAB-001), a humanized monoclonal antibody to amyloid beta… (More)
Is this relevant?
2009
2009
BACKGROUND Bapineuzumab, a humanized anti-amyloid-beta (Abeta) monoclonal antibody for the potential treatment of Alzheimer… (More)
Is this relevant?